Vertex Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX PHARMS, and when can generic versions of VERTEX PHARMS drugs launch?
VERTEX PHARMS has eight approved drugs.
There are fifty-one US patents protecting VERTEX PHARMS drugs.
There are seven hundred and eighty-six patent family members on VERTEX PHARMS drugs in fifty-four countries and eighty-four supplementary protection certificates in nineteen countries.
Drugs and US Patents for Vertex Pharms
Expired US Patents for Vertex Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Vertex Pharms | INCIVEK | telaprevir | TABLET;ORAL | 201917-001 | May 23, 2011 | 8,529,882 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expirations for VERTEX PHARMS
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Sign Up | ⤷ Sign Up |
International Patents for Vertex Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2769695 | ⤷ Sign Up |
Croatia | P20180328 | ⤷ Sign Up |
Australia | 2023201404 | ⤷ Sign Up |
Ukraine | 99895 | ⤷ Sign Up |
Serbia | 61408 | ⤷ Sign Up |
Poland | 365836 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vertex Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1320540 | 12C0018 | France | ⤷ Sign Up | PRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 |
2404919 | C02404919/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE (LUMACAFTOR); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65981 02.09.2016 |
3170818 | SPC/GB20/041 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF (A) 3-(6-(1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (I.E. LUMACAFTOR) AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE (I.E. IVACAFTOR) OR A PHARMACEUT; REGISTERED: UK EU/1/15/1059(NI) 20151124; UK PLGB 22352/0004 20151124 |
1320540 | C01320540/01 | Switzerland | ⤷ Sign Up | FORMER OWNER: VERTEX PHARMACEUTICALS INCORPORATED, US |
2826776 | CR 2021 00013 | Denmark | ⤷ Sign Up | PRODUCT NAME: EN KOMBINATION AF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) ....; REG. NO/DATE: EU/1/18/1306 20181106 |
1773816 | C 2015 027 | Romania | ⤷ Sign Up | PRODUCT NAME: IVACAFTOR SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAN-(5-HIDROXI-2,4-DITERT-BUTIL-FENIL)-4-OXO-1H-CHINOLIN-3-CARBOXAMIDA SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/12/782/001, EU/1/12/782/002; DATE OF NATIONAL AUTHORISATION: 20120723; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/782/001, EU/1/12/782/002; DATE OF FIRST AUTHORISATION IN EEA: 20120723 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.